What's happening to the peptide vendor market is not a series of random failures — it's a systematic enforcement escalation following a predictable pattern: regulatory restriction, then warning letters, then physical raids, then criminal prosecutions, then voluntary shutdowns of the vendors still standing. 8+ major vendors closed between mid-2025 and early 2026, the largest shakeout in the research peptide industry's history.
This article documents the full timeline, analyses the 3 forces driving the closures, and provides the verification framework for an unstable market. Peptigrity's independent lab tests, community reviews, and reviewed peptide shops persist regardless of which vendors come and go — that is the point of vendor-independent verification.
The Pattern: Warning Letters → Raids → Prosecutions → Voluntary Shutdowns
The enforcement escalation followed a clear trajectory across 3 stages — each more severe than the last — and vendors who recognised the pattern left before the next stage reached them.
Stage 1 — Regulatory restriction (late 2023–2024). The FDA moved 19 widely used peptides — including BPC-157, TB-500, CJC-1295, and Ipamorelin — to its Category 2 list in September 2023, effectively prohibiting compounding pharmacies from preparing them. Eli Lilly filed an ITC complaint against 12 tirzepatide importers in March 2024. By December 2024, the FDA issued warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research. The message: the regulatory framework is tightening. For the full regulatory landscape, see Are Peptides Legal? Regulatory Status by Country (2026).
Stage 2 — Physical enforcement (2025). In January 2025, the ITC issued a General Exclusion Order blocking all trademark-infringing tirzepatide imports. In February 2025, the FDA declared the semaglutide shortage resolved, closing the compounding loophole. In June 2025, FDA agents raided Amino Asylum's warehouse — the first physical raid on a major peptide vendor. The site went dark overnight. By September 2025, the FDA had issued 50+ warning letters to GLP-1 compounding pharmacies in a single month. The escalation from paper to physical enforcement was complete.
Stage 3 — Criminal prosecution + voluntary exits (late 2025–2026). Paradigm Peptides' founders pleaded guilty to federal charges in December 2025 after investigation revealed their SARM products contained undisclosed testosterone. Science.bio announced permanent closure in January 2026. On March 6, 2026, Peptide Sciences — the largest US vendor at ~$7.4M/month — posted a three-sentence shutdown notice and went dark. The vendors who read the pattern got out. The vendors who didn't faced raids or prosecution.
The Full Timeline: Every Major Vendor Action (2023–2026)
8+ major vendors closed between mid-2025 and early 2026 — alongside criminal prosecutions, warehouse raids, and the most aggressive regulatory campaign the research peptide industry has ever faced.
September 2023 — FDA moves 19 peptides to Category 2 (BPC-157, TB-500, CJC-1295, Ipamorelin, and others). Compounding pharmacies effectively prohibited from preparing these compounds. Patients pushed toward grey-market RUO vendors.
March 2024 — Eli Lilly files ITC complaint against 12 vendors importing tirzepatide.
December 2024 — FDA issues warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research for selling unapproved drug products.
January 2025 — ITC issues General Exclusion Order blocking all infringing tirzepatide imports.
February 2025 — FDA declares semaglutide shortage resolved. Legal basis for compounding semaglutide under Section 503A/503B disappears.
April 2025 — Eli Lilly sues Fella Health, Mochi Health over tirzepatide distribution.
June 2025 — FDA raids Amino Asylum warehouse. Site goes dark overnight. Payment processing terminated. Pending orders frozen. No customer communication. First physical raid on a major peptide vendor. Amino Asylum had ignored multiple FDA warning letters, marketed products for human consumption, sold prescription-only medications alongside peptides, and used trademarked pharmaceutical brand names. The raid signalled that the "research use only" disclaimer no longer provided protection.
August 2025 — Novo Nordisk sues 14 defendants — pharmacies and vendors compounding or distributing semaglutide products.
September 2025 — FDA issues 50+ warning letters to GLP-1 compounding pharmacies in a single month.
2025 (various) — Royal Research, Peptide Tech Labs, and American Research Labs go offline without public announcements. Part of the broader wave of smaller vendors exiting.
Earlier (pre-2025) — Tailor Made Compounding LLC pleads guilty to distributing unapproved drugs including BPC-157. $1.79 million forfeiture. All American Peptide owners plead guilty to conspiracy charges. $3M+ in forfeitures. Criminal prosecution precedent established.
December 2025 — Paradigm Peptides founders Matthew Kawa and Jennifer Stechkober plead guilty to federal charges. Products contained undisclosed testosterone — a controlled substance.
January 27, 2026 — Science.bio announces permanent closure. One of the most respected research chemical suppliers. No detailed public explanation. Committed to fulfilling outstanding orders and providing refunds — notably better customer handling than other closures.
February 2026 — HHS Secretary RFK Jr. announces approximately 14 of 19 Category 2 peptides returning to Category 1 — restoring compounding pharmacy access with physician prescription. Regulated pathway expands. SAFE Drugs Act introduced — expanded FDA authority over peptide distribution.
March 6, 2026 — Peptide Sciences voluntarily shuts down. Three-sentence notice. No advance warning. No refund process. ~$7.4M/month in revenue. The largest grey-market peptide vendor in US history, gone overnight. For the full analysis, see Peptigrity's Peptide Sciences shutdown deep-dive.
3 Forces Driving the Shutdowns
Three forces converged to make the grey-market peptide model unsustainable: FDA enforcement that escalated from letters to raids to criminal prosecution, pharmaceutical patent litigation from Eli Lilly and Novo Nordisk, and independent quality testing that exposed failures at vendors the community had trusted.
FDA Enforcement Escalation
The FDA moved from paper warnings to physical enforcement to supporting criminal prosecution in under 18 months. The agency began deploying AI to scrape vendor websites for dosing information, reconstitution guides, and user testimonials that contradicted "research use only" disclaimers. When a vendor's marketing, social media, and customer reviews make clear the products are used for human consumption, the "research" label provides no legal cover. The Amino Asylum raid was the inflection point — proving the FDA would commit physical enforcement resources, not just send letters.
Pharmaceutical Patent Litigation
Eli Lilly and Novo Nordisk opened a second enforcement front through civil litigation. Lilly sued telehealth companies distributing tirzepatide (April 2025), secured ITC exclusion orders blocking imports, and entered exclusive agreements with telehealth platforms prohibiting them from working with compounders. Novo Nordisk sued 14 semaglutide distributors (August 2025). Any vendor carrying GLP-1 compounds faced litigation from companies with effectively unlimited legal budgets. Peptide Sciences had already delisted both tirzepatide and semaglutide under this pressure — a signal of the legal exposure even the largest vendor couldn't absorb. INTERPOL's Operation Pangea XVII seized 50.4 million doses of illicit pharmaceuticals globally, with counterfeit GLP-1 products flagged specifically.
Quality Testing Failures
Independent testing platforms exposed inconsistencies that damaged the entire market's credibility. Finnrick analysed 123 Peptide Sciences samples across 10 peptides: ipamorelin scored A (9.2/10), BPC-157 scored A (7.8/10) — but CJC-1295 scored E (4.3/10), tesamorelin scored E, and retatrutide scored E across 37 samples with a counterfeit detection flagged in November 2025. A vendor can survive regulatory ambiguity. A vendor cannot survive regulatory ambiguity and documented quality failures simultaneously. The testing data proved that even the most established vendor's reliability was compound-specific, not universal.
What This Means for Peptide Buyers
The grey-market "research use only" model is being dismantled — not because peptides are being banned, but because the unregulated distribution channel is being shut down while the regulated pathway (compounding pharmacies with physician prescriptions) is expanding.
The February 2026 HHS announcement restoring ~14 peptides to Category 1 is the key signal: regulated access is growing. The compounds are not disappearing — the unregulated channel for obtaining them is.
For buyers still using RUO vendors, the implications are direct. The remaining vendors face the same 3 converging pressures. More closures are expected. Your current vendor could be the next Peptide Sciences — posting a three-sentence notice and disappearing overnight with your pending order. The Finnrick data proves that quality is compound-specific: a vendor's BPC-157 may score A while their retatrutide scores E. Blind trust in any vendor is the risk.
The solution: build verification infrastructure that does not depend on any single vendor. Peptigrity's lab test data, community reviews, and trust scores persist regardless of which individual vendors enter or exit the market. When Peptide Sciences shut down, every data point on Peptigrity about every other vendor remained intact. Buyers who had verified alternatives through the platform were unaffected. Buyers who relied solely on Peptide Sciences started from zero.
How to Verify Any Vendor Before It's Too Late
Don't wait for your vendor to become the next headline — verify now using Peptigrity's vendor-independent data.
Search vendors on peptigrity.com/shops — trust score, ✓ Lab Verified badge, community-submitted test count, review volume. A vendor with zero Peptigrity presence is unverified.
Cross-reference compounds on peptigrity.com/lab-tests — filter by vendor + compound. Compare purity data across multiple vendors for the same compound. Quality is compound-specific, not vendor-wide.
Read community reviews — 5 sub-ratings per review. Look for patterns across multiple reviews.
Apply the 7-check framework from How to Verify Peptide Quality Before You Buy and the Buyer's Checklist.
Red flags that preceded previous shutdowns: selling GLP-1 compounds (semaglutide, tirzepatide) despite ITC exclusion orders, marketing language implying human use, no third-party CoAs, recently delisting compounds under patent pressure, and radio silence on customer communication.
For compound-specific verification beyond the general framework, Peptigrity's buying guides cover 15+ compounds with unique analytical insights per compound — from BPC-157 methionine oxidation to tirzepatide semaglutide substitution to CJC-1295 DAC/no-DAC version confusion.
Frequently Asked Questions
Will more peptide vendors shut down?
The regulatory pressure has only intensified. The enforcement pattern — warning letters, raids, prosecutions — continues. The SAFE Drugs Act proposes expanded FDA authority. More closures are expected. Build verification infrastructure on a platform (peptigrity.com/shops) that persists regardless of individual vendor stability.
Are peptides being banned?
No. Peptides themselves are not being banned. The unregulated grey-market distribution channel is being shut down. In February 2026, HHS restored ~14 of 19 previously restricted peptides to Category 1 — expanding legal access through compounding pharmacies with physician prescriptions. The regulated pathway is growing while the unregulated pathway shrinks.
What should I do if my vendor shuts down?
If you have unfulfilled orders, contact your bank for a chargeback immediately — most cards allow chargebacks within 60–120 days. Document everything (order confirmation, payment receipts). For future purchases, verify vendors through peptigrity.com/shops BEFORE ordering. Start small with any new vendor (1–2 vials).
Does Peptigrity recommend which vendor to use?
No. Peptigrity is vendor-independent. It provides lab test data, community reviews, and trust scores — not vendor recommendations. The platform's value is that it persists when individual vendors don't.
How do I know if my current vendor is at risk?
Red flags: selling GLP-1 compounds despite ITC exclusion orders, marketing that implies human use beyond "research only," no verifiable third-party CoAs, recent compound delisting under patent pressure, and poor responsiveness to customer inquiries. Check your vendor's profile on peptigrity.com/shops for community assessment.
This article is for educational and informational purposes only and does not constitute legal or purchasing advice. The regulatory landscape described reflects information available as of April 2026 and is subject to change. Research peptides are not approved by the FDA for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
